1.Weiner DA. Calcium channel blockers. Med Clin North Am 1988; 72: 83-115.
2.Mirkhani H, Omrani GR, Ghiaee S, Mahmoudian M. Effects of mebudipine and dibudipine, two new calcium- channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. J Pharm Pharmacol 1999; 51: 617-622.
3.Parmley WW. A delayed answer to the calcium blocker question. J Am Coll Cardiol 1996; 27:510-511.
4.Safak C, Simsek R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini Rev Med Chem 2006; 6: 747-755.
5.Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67:1309-1327.
6.Goldmann S, Stoltefuss J. 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew Chem Int Edit 1991; 30: 1559-1578.
7.Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50:560-586.
8.Hadizadeh F, Fatehi-Hassanabad Z, Fatehi-Hassanabad M, Beheshtizadeh A, Nabati F. Synthesis and antihypertensive activity of novel 4-[1-(4-X-benzyl)-5-imidazolyl] dihydropyridines in rat. Res Pharm Sci 2007; 2:87-93.
9.Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004; 22:1641-1648.
10.Nekooeian AA, Khalili A, Javidnia K, Mehdipour AR, Miri R. Antihypertensive effects of some new nitroxyalkyl 1,4-dihydropyridine derivatives in rat model of two-kidney, one-clip hypertension. Iran J Pharm Res 2009; 8:193-199.
11.Langs DA, Strong PD, Triggle DJ. Receptor model for the molecular basis of tissue selectivity of 1, 4- dihydropyridine calcium channel drugs. J Comput Aided Mol Des 1990; 4:215-230.
12.Mager PP, Coburn RA, Solo AJ, Triggle DJ, Rothe H. QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead. Drug Des Discov 1992; 8: 273-289.
13.Rovnyak GC, Kimball SD, Beyer B, Cucinotta G, DiMarco JD, Gougoutas J, et al. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J Med Chem 1995; 38:119-129.
14.Hosseini M, Miri R, Amini M, Mirkhani H, Hemmateenejad B, Ghodsi S, et al. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents. Arch Pharm (Weinheim) 2007; 340: 549-556.
15.Lavilla R. Recent developments in the chemistry of dihydropyridines. J Chem Soc Perkin Trans 1 2002: 1141-1156.
16.Hadizadeh F, Fatehi-Hassanabad Z, Bamshad M, Poorsoghat H, Fatehi-Hassanabad M. Synthesis and antihypertensive activity of new 1,4-dihydropyridines. Indian J Chem section B 2005; 44B:2343-2347.
17.Hadizadeh F, Fatehi M, Fatehi-Hassanabad Z, Zandieh M. Effects of 4-(2-Alkylthio-1-benzyl-5-imidazolyl)- Dihydropyridines on the isolated rat colon and right atrium contractility. Iran J Basic Med Sci 2005; 11:159-165.
18.Miri R, Javidnia K, Hemmateenejad B, Tabarzad M, Jafarpour M. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4- dihyropyridine). Chem Biol Drug Des 2009; 73:225-235.
19.Valdivielso JM, Macias JF, Lopez-Novoa JM. Cardiovascular effects of elgodipine and nifedipine compared in anaesthetized rats. Eur J Pharmacol 1997; 335:193-198.